Education
About Us
Working with TipRanks
Follow Us
Aardvark Therapeutics, Inc. (AARD)
NASDAQ:AARD
RESEARCH TOOLSreports
Total Valuation
Aardvark Therapeutics, Inc. has a market cap or net worth of $241.48M. The enterprise value is $175.16M.
Market Cap$241.48M
Enterprise Value$175.16M
Share Statistics
Aardvark Therapeutics, Inc. has 21,695,920 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding21,695,920
Owned by Insiders42.27%
Owned by Institutions31.23%
Financial Efficiency
Aardvark Therapeutics, Inc.’s return on equity (ROE) is -0.29 and return on invested capital (ROIC) is -31.25%.
Return on Equity (ROE)-0.29
Return on Assets (ROA)-0.27
Return on Invested Capital (ROIC)-31.25%
Return on Capital Employed (ROCE)-0.31
Revenue Per Employee0.00
Profits Per Employee-1.21M
Employee Count17
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Aardvark Therapeutics, Inc. is -8.97. Aardvark Therapeutics, Inc.’s PEG ratio is 0.43.
PE Ratio-8.97
PS Ratio0.00
PB Ratio-5.31
Price to Fair Value2.56
Price to FCF-31.72
Price to Operating Cash Flow-31.72
PEG Ratio0.43
Income Statement
In the last 12 months, Aardvark Therapeutics, Inc. had revenue of 0.00 and earned -20.59M in profits. Earnings per share was -1.59.
Revenue0.00
Gross Profit0.00
Operating Income-22.79M
Pretax Income-20.59M
Net Income-20.59M
EBITDA-22.79M
Earnings Per Share (EPS)-1.59
Cash Flow
In the last 12 months, operating cash flow was -23.07M and capital expenditures -11.00K, giving a free cash flow of -23.08M billion.
Operating Cash Flow-23.07M
Free Cash Flow-23.08M
Free Cash Flow per Share-1.06
Dividends & Yields
Aardvark Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.02
52-Week Price Change-16.32%
50-Day Moving Average10.08
200-Day Moving Average―
Relative Strength Index (RSI)51.71
Average Volume (3m)40.47K
Important Dates
Aardvark Therapeutics, Inc. upcoming earnings date is May 14, 2025, TBA Not Confirmed.
Last Earnings DateMar 31, 2025
Next Earnings DateMay 14, 2025
Ex-Dividend Date―
Financial Position
Aardvark Therapeutics, Inc. as a current ratio of 15.05, with Debt / Equity ratio of -0.47%
Current Ratio15.05
Quick Ratio15.05
Debt to Market Cap<0.01
Net Debt to EBITDA2.67
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Aardvark Therapeutics, Inc. has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Aardvark Therapeutics, Inc. EV to EBITDA ratio is -5.44, with an EV/FCF ratio of -6.81.
EV to Sales0.00
EV to EBITDA-5.44
EV to Free Cash Flow-6.81
EV to Operating Cash Flow-6.85
Balance Sheet
Aardvark Therapeutics, Inc. has $151.26M in cash and marketable securities with $726.00K in debt, giving a net cash position of -$150.53M billion.
Cash & Marketable Securities$151.26M
Total Debt$726.00K
Net Cash-$150.53M
Net Cash Per Share-$6.94
Tangible Book Value Per Share-$4.23
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Aardvark Therapeutics, Inc. is $31.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$31.50
Price Target Upside319.44% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast―
EPS Growth Forecast―